<?xml version="1.0" encoding="UTF-8"?>
<p>With a drug trial at the heart of the book, McCarthy argues the key solution lies in discovering new drugs. Yet, as he vividly points out, returns on investment are awful for antimicrobial development—and getting worse. Other avenues being explored—vaccines, phages, probiotics, combination therapies—seem as likely to break us out of unsustainable open-ended drug discovery treadmills. Whatever the answer, McCarthy’s book makes a strong case that we can make serious inroads on antimicrobial resistance if we focus scientific and clinical firepower on the problem. His stories of patients show that we really must.</p>
